Cyclin-dependent kinases as a therapeutic target for stroke.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 10944192.
- Also identified by PMC identifier 27851.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cyclin-dependent kinases (CDKs) are commonly known to regulate cell proliferation. However, previous reports suggest that in cultured postmitotic neurons, activation of CDKs is a signal for death rather than cell division. We determined whether CDK activation occurs in mature adult neurons during focal stroke in vivo and whether this signal was required for neuronal death after reperfusion injury. Cdk4/cyclin D1 levels and phosphorylation of its substrate retinoblastoma protein (pRb) increase after stroke. Deregulated levels of E2F1, a transcription factor regulated by pRb, are also observed. Administration of a CDK inhibitor blocks pRb phosphorylation and the increase in E2F1 levels and dramatically reduces neuronal death by 80%. These results indicate that CDKs are an important therapeutic target for the treatment of reperfusion injury after ischemia.
Medical subject headings
- Carrier Proteins
- Cell Cycle Proteins
- Cerebrovascular Circulation
- Cyclin-Dependent Kinases
- DNA-Binding Proteins
- Enzyme Inhibitors
- Flavonoids
- Ischemic Attack, Transient
- Piperidines
- Proto-Oncogene Proteins
- Reperfusion Injury